261 related articles for article (PubMed ID: 37426807)
41. Continuation of trastuzumab beyond progression in HER2-positive advanced esophagogastric cancer: a meta-analysis.
Ter Veer E; van den Ende T; Creemers A; de Waal L; van Oijen MGH; van Laarhoven HWM
Acta Oncol; 2018 Dec; 57(12):1599-1604. PubMed ID: 30264641
[TBL] [Abstract][Full Text] [Related]
42. Survival outcomes of beta-blocker usage in HER2-positive advanced breast cancer patients: a retrospective cohort study.
Hsieh HH; Wu TY; Chen CH; Kuo YH; Hour MJ
Ther Adv Drug Saf; 2023; 14():20420986231181338. PubMed ID: 37359444
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and safety of taxanes combined with chemotherapy drugs in advanced triple negative breast cancer: A meta-analysis of 26 randomized controlled trials.
Huang Q; Mei Z; Han X
Front Oncol; 2022; 12():972767. PubMed ID: 36119468
[TBL] [Abstract][Full Text] [Related]
44. The efficacy and safety of Xueshuantong (lyophilized) for injection in the treatment of unstable angina pectoris: A systematic review and meta-analysis.
Xi J; Wei R; Cui X; Liu Y; Xie Y
Front Pharmacol; 2023; 14():1074400. PubMed ID: 37089918
[No Abstract] [Full Text] [Related]
45. A Meta-Analysis to Assess the Efficacy of HER2-Targeted Treatment Regimens in HER2-Positive Metastatic Colorectal Cancer (mCRC).
Chitkara A; Bakhtiar M; Sahin IH; Hsu D; Zhang J; Anamika F; Mahnoor M; Ahmed R; Gholami S; Saeed A
Curr Oncol; 2023 Sep; 30(9):8266-8277. PubMed ID: 37754515
[TBL] [Abstract][Full Text] [Related]
46. HER2-targeted regimens after prior trastuzumab for patients with HER2-positive unresectable, locally advanced or metastatic breast cancer: a network meta-analysis of randomized controlled trials.
Li X; Wu S; Zhang L; Zhu J; Xu B
Ann Transl Med; 2020 Dec; 8(24):1634. PubMed ID: 33490146
[TBL] [Abstract][Full Text] [Related]
47. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.
Loi S; Giobbie-Hurder A; Gombos A; Bachelot T; Hui R; Curigliano G; Campone M; Biganzoli L; Bonnefoi H; Jerusalem G; Bartsch R; Rabaglio-Poretti M; Kammler R; Maibach R; Smyth MJ; Di Leo A; Colleoni M; Viale G; Regan MM; André F;
Lancet Oncol; 2019 Mar; 20(3):371-382. PubMed ID: 30765258
[TBL] [Abstract][Full Text] [Related]
48. Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer.
Yu YF; Wang Y; Fu TP; Chen K; Liu JQ; Yao HR
Breast Cancer Res Treat; 2018 Apr; 168(2):337-348. PubMed ID: 29188398
[TBL] [Abstract][Full Text] [Related]
49. Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1.
Toi M; Shao Z; Hurvitz S; Tseng LM; Zhang Q; Shen K; Liu D; Feng J; Xu B; Wang X; Lee KS; Ng TY; Ridolfi A; Noel-Baron F; Ringeisen F; Jiang Z
Breast Cancer Res; 2017 Apr; 19(1):47. PubMed ID: 28399902
[TBL] [Abstract][Full Text] [Related]
50. Efficacy of targeted therapy in patients with HER2-positive non-small cell lung cancer: A systematic review and meta-analysis.
Wu HX; Zhuo KQ; Wang K
Br J Clin Pharmacol; 2022 May; 88(5):2019-2034. PubMed ID: 34820879
[TBL] [Abstract][Full Text] [Related]
51. Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial.
Song Z; Li Y; Chen S; Ying S; Xu S; Huang J; Wu D; Lv D; Bei T; Liu S; Huang X; Xie C; Wu X; Fu J; Hua F; Wang W; Xu C; Gao C; Cai S; Lu S; Zhang Y
BMC Med; 2022 Feb; 20(1):42. PubMed ID: 35101045
[TBL] [Abstract][Full Text] [Related]
52. Systemic Therapy for Patients with HER2-Positive Breast Cancer and Brain Metastases: A Systematic Review and Meta-Analysis.
Werter IM; Remmelzwaal S; Burchell GL; de Gruijl TD; Konings IR; van der Vliet HJ; Menke-van der Houven van Oordt CW
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428705
[TBL] [Abstract][Full Text] [Related]
53. Pathologic Complete Response Achieved in Early-Stage HER2-Positive Breast Cancer After Neoadjuvant Therapy With Trastuzumab and Chemotherapy vs. Trastuzumab, Chemotherapy, and Pertuzumab: A Systematic Review and Meta-Analysis of Clinical Trials.
Fazal F; Bashir MN; Adil ML; Tanveer U; Ahmed M; Chaudhry TZ; Ijaz AA; Haider M
Cureus; 2023 May; 15(5):e39780. PubMed ID: 37398703
[TBL] [Abstract][Full Text] [Related]
54. Safety and efficacy study of oral metronomic vinorelbine combined with trastuzumab (mNH) in HER2-positive metastatic breast cancer: a phase II trial.
Wang Z; Liu J; Ma F; Wang J; Luo Y; Fan Y; Yuan P; Zhang P; Li Q; Li Q; Xu B
Breast Cancer Res Treat; 2021 Jul; 188(2):441-447. PubMed ID: 33895900
[TBL] [Abstract][Full Text] [Related]
55. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Chan A; Delaloge S; Holmes FA; Moy B; Iwata H; Harvey VJ; Robert NJ; Silovski T; Gokmen E; von Minckwitz G; Ejlertsen B; Chia SKL; Mansi J; Barrios CH; Gnant M; Buyse M; Gore I; Smith J; Harker G; Masuda N; Petrakova K; Zotano AG; Iannotti N; Rodriguez G; Tassone P; Wong A; Bryce R; Ye Y; Yao B; Martin M;
Lancet Oncol; 2016 Mar; 17(3):367-377. PubMed ID: 26874901
[TBL] [Abstract][Full Text] [Related]
56. Trastuzumab Deruxtecan (DS-8201a): The Latest Research and Advances in Breast Cancer.
Andrikopoulou A; Zografos E; Liontos M; Koutsoukos K; Dimopoulos MA; Zagouri F
Clin Breast Cancer; 2021 Jun; 21(3):e212-e219. PubMed ID: 32917537
[TBL] [Abstract][Full Text] [Related]
57. Efficacy Evaluation of Bevacizumab Combined with Capecitabine in the Treatment of HER2-Negative Metastatic Breast Cancer: A Meta-Analysis.
Hu Y; Chen P; Xiang F
J Oncol; 2023; 2023():8740221. PubMed ID: 36816360
[TBL] [Abstract][Full Text] [Related]
58. Retrospective Study on the Efficacy and Safety of Pyrotinib-Based Therapy for HER2-Positive Nonbreast Advanced Solid Tumors.
Wang J; Zhang B; Cheng X; Li Q; Lv H; Nie C; Chen B; Xu W; Zhao J; He Y; Tu S; Chen X
J Oncol; 2022; 2022():4233782. PubMed ID: 35368895
[TBL] [Abstract][Full Text] [Related]
59. Efficacy and safety of oncolytic virus combined with chemotherapy or immune checkpoint inhibitors in solid tumor patients: A meta-analysis.
Liu X; Zhang J; Feng K; Wang S; Chen L; Niu S; Lu Q; Fang Y
Front Pharmacol; 2022; 13():1023533. PubMed ID: 36452227
[No Abstract] [Full Text] [Related]
60. Efficacy and Safety of Anti-HER2 Agents in Combination With Chemotherapy for Metastatic HER2-Positive Breast Cancer Patient: A Network Meta-Analysis.
Zhang X; Leng J; Zhou Y; Mao F; Lin Y; Shen S; Sun Q
Front Oncol; 2021; 11():731210. PubMed ID: 34490125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
